Biotech company working on a cure for Colorblindness

People with congenital colorblindness can see about 1 percent of the colors that a typical person can, and the condition can have negative impacts on their lives. Colorblindness can prevent people from becoming pilots or electricians, as well as limit their vision at night, putting themselves and others in danger.
Now a pair of researchers are teaming up with the startup Avalanche Biotechnologies to develop a genetic therapy that could cure colorblindness. Colorblindness, which affects 32 million Americans, is the result of a genetic mutation on the X chromosome.
Since men only have one X chromosome, they are more likely to be colorblind than women, who can often overcome a possible mutation with their second X chromosome. Since genes hold the key to colorblindness, vision researchers Jay and Maureen Neitz believe that gene therapy could hold the cure.
Six years ago, they were able to correct a spider monkey’s congenital colorblindness in their lab at the University of Washington by delivering new genes to the retina, the part of the eye that responds to color.
The genes added an extra color receptor cone to the retina of the monkeys, who had been colorblind since birth. The researchers were surprised that the monkeys had the neural pathways to make sense of the new information, allowing them to see the same colors as non-colorblind monkeys.